To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
Reuters file photo Vials of COVID-19 vaccine made by various manufacturers are seen in this image taken Jan. 16.
The Yomiuri Shimbun
15:39 JST, July 7, 2022
KM Biologics Co. plans to file an application with the Health, Labor and Welfare Ministry for approval of its under-development novel coronavirus vaccine in September, at the earliest, the company said Wednesday.
The Kumamoto-based pharmaceutical company said it will use the so-called urgent approval system, which shortens the final stage of the approval process, with the aim of supplying the vaccine by the end of fiscal 2022.
KM Biologics said its COVID-19 vaccine has been confirmed to be safe and is presumed to be more effective than vaccines already in practical use.
The company’s product is an inactivated vaccine that uses a noninfective, nontoxic virus, and is planned to be administered three times to 18-to-40-year-olds.
About 2,500 people participated in the interim clinical trial, which started in April and measured levels of neutralizing antibodies after three inoculations. Based on data from the final phase of testing, it was found that test participants had a 99.9% probability of having higher levels of neutralizing antibodies than people who had received two doses of the AstraZeneca vaccine. As a result, KM Biologics’ vaccine is presumed to be effective, the company said. KM Biologics added that the frequency of adverse reactions was about the same as that of seasonal influenza vaccines, further underlining the product’s safety.
